#### ORIGINAL ARTICLE

# Thrombotic and nonthrombotic hepatic artery complications in adults and children following primary liver transplantation with long-term follow-up in 1000 consecutive patients\*

Ashokkumar Jain,<sup>1,2</sup> Guilherme Costa,<sup>2</sup> Wallis Marsh,<sup>2</sup> Paulo Fontes,<sup>2</sup> Michael Devera,<sup>2</sup> George Mazariegos,<sup>2</sup> Jorge Reyes,<sup>3</sup> Kusum Patel,<sup>2</sup> Ravi Mohanka,<sup>1</sup> Mary Gadomski,<sup>2</sup> John Fung<sup>4</sup> and Amadeo Marcos<sup>2</sup>

- 1 Department of Surgery, Division of Transplantation, University of Rochester Medical Centre, Rochester, NY, USA
- 2 Thomas E Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, USA
- 3 Transplant Services, Children's Hospital and Regional Medical Centre, Seattle, WA, USA
- 4 Transplant Centre, Department of Surgery, The Cleveland Clinic Foundation, Cleveland, OH, USA

#### Keywords

early hepatic artery thrombosis, hepatic artery pseudo-aneurysm, hepatic artery stenosis, hepatic artery thrombosis, intermediate hepatic artery thrombosis, liver transplantation.

# Correspondence

Ashokkumar Jain MD, Department of Surgery, Division of Transplantation, University of Rochester Medical Centre, Box SURG, 601 Elmwood Avenue, Rochester, NY 14642, USA. Tel.: (585) 275 2924; fax: (585) 506 0054; e-mail: ashok\_jain@urmc.rochester.edu

\*Data presented at the 25th Annual Scientific Meeting, The American Society of Transplant Surgeons (ASTS) May 1999, Chicago, IL, USA and Fifth Congress of the International Liver Transplantation Society, August 26–28, 1999, Pittsburgh, PA, USA.

Received: 5 July 2005

Revision requested: 12 August 2005 Accepted: 6 September 2005

doi:10.1111/j.1432-2277.2005.00224.x

# Introduction

Results of liver transplantation (LTx) have improved significantly in the last three decades [1]. Graft loss from acute or chronic rejection is rare [2–4] with currently available modern immunosuppressive agents. One of the commonest reasons of early graft loss is hepatic artery

# **Summary**

Arterial complications have a major impact on survival after liver transplantation (LTx). The aim of this study was to examine arterial complications in adults and children after LTx. A total of 1000 consecutive primary LTx patients [mean age 40.5 years: 600 males, 400 females, 834 adults; 166 children (age <18 years)] were studied. Forty-two patients (4.2%; 31 adults, 11 children) developed hepatic artery thrombosis (HAT). Thrombosis in children occurred significantly early (mean 5.4 days) compared with adults (mean 418.7 days, P=0.0001). Nonthrombotic complications occurred in 30 patients (29 adults, one child). Overall, 13-year patient survival after HAT was 43.2% (72.7% children, 32.9% adults). For nonthrombotic complications, 54.3% of adults died and 69.4% grafts were lost. An overall incidence of 4.2% thrombotic and 3.2% nonthrombotic complications was observed. Rate of HAT was higher in children, but survival was better compared with adults.

thrombosis (HAT). Risk factors for HAT that have been reported in the literature include anatomical variations, smaller hepatic artery diameter with reduced blood flow and hyper-coagulable states because of protein S, protein C, antithrombin-III deficiency or a rise in hematocrit because of dehydration [5–9]. However, there are very few studies that describe the variety of complications

Hepatic artery thrombosis Jain et al.

related to hepatic artery that can be encountered after LTx over a long period of time in all age groups.

#### Aim

To examine the rate of hepatic artery complications in adults and children after primary liver transplant from a single institution and their long-term outcomes.

#### Patient and methods

One thousand consecutive patients who underwent primary LTx between August 1989 and December 1992 under tacrolimus-based immunosuppressive regimen were included in this study. There were 600 males and 400 females; 834 recipients were adults (age >18 years) and the remaining 166 were children (age ≤18 years). All patients were followed up, until August 2004. The mean follow-up period was 13.4 years (range 11.7–15). The immunosuppressive protocol used in this study population and their diagnosis has been previously reported [4,10]. Main hepatic artery with aortic cuff of the donor was anastomosed to the confluence of the main hepatic artery and gastro-duodenal artery in the recipient. Hepatic arterial anastomosis in children was performed using optical loupes of 3x or greater magnification. Usually, 7-0 or 8-0 prolene sutures were used in a running fashion. All children were commenced on anticoagulation during the first postoperative week when the international normalized ratio was ≤2.0. Anticoagulation was not used in adult population.

All patients underwent routine color duplex ultrasound examination not only during the first postoperative week, but also when abnormal liver function was clinically suspected and in febrile illness. Abnormal ultrasonic findings were evaluated by hepatic artery angiography.

Data were analyzed retrospectively after obtaining institutional review board exemption-approved protocol. A database was created after deleting patient-identifiable information by two independent brokers from an existing database. Based on the nature of the complication, patients were divided into two broad groups: thrombotic and non-thrombotic. Patients in the thrombotic group were further subdivided into early (<1 month), intermediate (1–6 months) and late (>6 months), depending on the period after LTx. Adults and children were separately examined for pattern of complications, rate of complications and survival outcomes.

### Statistical analysis

Results are described as mean  $\pm$  SD. The difference in categorical values between adults and children were analyzed using the Pearson chi-square test. Differences

between mean values were calculated using Student's t-test. Patient and graft survival were calculated and plotted for different groups and subgroups using Kaplan–Meier statistics. The survival differences between these groups were analyzed using the log-rank formula. P < 0.05 was considered significant. SPSS® version 13.0 for Windows® software (SPSS Inc., Chicago, IL, USA) was used for statistical analyses.

#### Results

Different types of arterial complications were observed and they were divided into two broad groups: thrombotic and nonthrombotic. The management strategy and survival outcomes were different in both groups.

# Thrombotic complications

Thrombosis was the most common among all arterial complications observed. It was also the most common cause of graft loss and death in the immediate postoperative period. Overall, 42 patients (4.2%) developed HAT, of which 11 were children (6.7%) and 31 adults (3.7%). The rate of HAT in children was almost double as compared to adults, but the difference was not statistically significant (P = 0.088) (Tables 1 and 2).

The time of diagnosis of HAT after LTx was different for children and adults. In children, HAT occurred within the first 2 weeks after LTx, while of 31 thrombosis in adults, 10 (32%) occurred in the first month post-LTx (mean  $8.8 \pm 6.8$  days), eight (25.8%) occurred within 1–6 months post-LTx (mean  $103.6 \pm 45$  days), and the remaining 13 (41.9%) occurred 6 months post-LTx (mean 922.9  $\pm$  606.7 days). The difference was statistically significant (P = 0.0001).

#### Nonthrombotic complications

Mean donor age was  $41.5 \pm 16.4$  years for early,  $32.9 \pm 10.6$  years for intermediate and  $40.1 \pm 15.8$  years for late HAT (P=0.44). The total ischemic time was  $851.8 \pm 134.0$ ,  $780.6 \pm 122.6$  and  $918.9 \pm 208.4$  min for early, intermediate and late HAT, respectively (P=0.2). The various types of nonthrombotic complications observed in this series consisted of arterial stenosis, redundant artery with kink, and hepatic artery pseudoaneurysm. Thirty patients (3.0%) were diagnosed with nonthrombotic complications, of which one was a child and the remaining 29 were adults. The difference in the incidence of nonthrombotic complications among adults and children was statistically significant (P=0.0001).

In adults, stenosis was found at various anatomical regions on angiogram. The most common site of

**Table 1.** Incidence of hepatic artery complications.

Complication	Children n (%)	Adults n (%)	Total <i>n</i> (%)
Thrombotic	11 (6.6)	31 (3.8)	42 (4.2)
Nonthrombotic	1 (0.6)	29 (3.5)	30 (3.0)
Anastomotic stenosis	1	9	10
Proximal main hepatic artery stenosis	0	5	5
Redundant hepatic artery with kink	0	3	3
Pseudo-aneurysm	0	4	4
Right hepatic artery stenosis	0	2	2
Left hepatic artery stenosis	0	1	1
Celiac axis stenosis	0	1	1
Infra-renal aortic graft stenosis	0	1	1
Redundant infra-renal aortic graft with kink	0	1	1
Anastomotic stenosis with celiac axis stenosis	0	1	1
Right and left hepatic artery stenosis	0	1	1
Total	12 (1.2)	60 (6.0)	72 (7.2)
Mean time to thrombosis in days (mean $\pm$ SD)	$5.4 \pm 4.5$	418.7 ± 582.3	310.5 ± 531.

stenosis was anastomosis of the hepatic artery (n=9) or iliac graft (n=1). This was followed by proximal hepatic artery postanastomotic stenosis (n=5), redundant length with kink in hepatic artery (n=3) or iliac graft (n=1), isolated right (n=2) and left (n=1) hepatic artery stenosis, infra-renal aorto-iliac graft stenosis (n=1), stenosis at the origin of native celiac axis (n=1), combination of right and left hepatic artery stenosis (n=1) and combination of celiac axis and anastomotic site stenosis (n=1). In addition, four patients in the adult population developed pseudo-aneurysm of the hepatic artery at the site of anastomosis (Tables 1 and 3).

# Management of thrombotic complications and outcome

#### Children

Five children received re-transplantation (cases 31–36). One of them subsequently died (case 36) and four survived. In one, the artery was reconstructed surgically (case 41) and the child survived. One was treated with streptokinase and Fogarty embolectomy, but did not respond (case 38) and died before re-transplantation. In one child, only the right hepatic artery was thrombosed with some blood flow in the left hepatic artery with collateral formation and he survived (case 42). The other three children were kept under observation awaiting re-transplantation (cases 37, 39 and 40). Two of these three children survived and one died.

# Adult

Early thrombosis (within 1 month from LTx)

In 31 cases of thrombosis, 10 patients had early thrombosis (cases 1–10), three of these patients (cases 2, 3 and 7)

had aortic iliac graft thrombosis, one had a clotted right hepatic artery (case 10) and the remaining six had main HAT. Nine of 10 patients underwent re-transplantation and one patient (case 8) improved while waiting for re-transplantation, but he subsequently died from recurrent hepatitis C viral (HCV) infection. Five of nine re-transplanted patients died from aspergilliosis (0.5 month), sepsis (6.8 months), recurrent primary sclerosing cholangitis (34 months), multi-organ failure (4.5 months) and pancreatitis (5.0 months) (Table 2).

# Intermediate thrombosis (1–6 months from LTx)

Of eight patients with intermediate thrombosis (cases 11–18), four patients underwent re-transplantation (cases 11, 12, 14 and 17), one of them with an infra-renal aortoiliac graft (case 14) while four patients were under observation. Two among these four re-transplanted patients required a third transplantation 30 and 45 days later for thrombosis in the second allograft (cases 12 and 17, respectively). Both died at 9 and 21 months after second re-transplantation. The remaining two are alive at 116 and 109 months (Table 2).

All four patients who were under observation subsequently died of liver failure (n = 1), recurrent hepatocellular carcinoma (n = 2) and intrabdominal bleeding from pancreatic pseudocyst (n = 1).

# *Late thrombosis (>6 months from LTx)*

Of the 13 patients who presented with late thrombosis (cases 19–31), five had an infra-renal aorto-iliac graft. Eight of these 13 patients underwent re-transplantation and five were under observation. Two patients after re-transplantation, and two patients who did not receive

 Table 2.
 Demographics and outcome of thrombotic complications.

And All All All All All All All All All Al		Age at		Primary	Time to diagnosis (days	is (days				Pt. survival
1	S no.	LTx (years)	Gender	diagnosis	from LTx)		Anatomical site	Management	Outcome	(months)
19.1   M HeV Enty   1   Donor HA Reix African Series   Asset Ser	Adults									
5.6.8         M.         HCV         1         Infra real list griff         Refx         Dued of sepsis           5.5.1         M.         HCV         2         Donor HA         Refx         Due of Negatic failure           4.4.3         F         HCV         1         Donor HA         Refx         Due of Negatic failure           4.4.3         F         HCV         1         Donor HA         Refx         Due of NoSF           5.5.3         F         HCV and HCC         1         Donor HA         Refx         Due of NoSF           5.6.5         M         HCV and HCC         1         Donor HA         Refx         Due of percent HCC           5.6.1         M         Advertisency         Inferenced HCC         0         Donor HA         Refx         Due of Repair challure           5.6.1         M         Advertisency         Inferenced HCC         0         Donor HA         Refx         Due of Repair challure           6.0         M         Advertisency         Inferenced HCC         1         Donor HA         Refx         Due of Repair challure           6.0         M         Advertisency         Inferenced HCC         1         Donor HA         Refx         Due of Refx	_	19.1	Σ	HBV	Early	_	Donor HA	ReTx	Alive	96.1
55.1         M         HCV         2         Infra ental like graft         ReTX         Alive           44.3         F         PRC         2         Infra ental like graft         ReTX         Dake the plant fallure           44.3         F         PRC         10         Infra ental like graft         ReTX         Alive         Proceeding           55.7         F         HEV         10         Donor HA         ReTX         Alive of regard fallure           55.7         M         FICH and HCC         19         Donor HA         ReTX         Died of hepatic fallure           52.1         M         ALGERIAGNOS         Intermedate         46         Donor HA         ReTX         Died of hepatic fallure           52.1         M         ALGERIAGNOS         Intermedate         46         Donor HA         ReTX         Died of hepatic fallure           53.1         M         HCV         Auto-immune         49         Donor HA         ReTX         Died of hepatic fallure           66         M         HCV         HCV         Auto-immune         49         Donor HA         ReTX         Died of hepatic fallure           55.3         M         HCV         HCV         Auto-immune         49	2	50.8	Σ	HCV		<b>—</b>	Infra renal iliac graft	ReTx	Died of sepsis	8.9
3.4   M PSC	m	55.1	Σ	HCV		2	Infra renal iliac graft	ReTx	Alive	52.9
443         F         BBC         10         Donot HA         RefX         Alive           53         F         HCV         HCV         12         Infra renal like graft         RefX         Alive           35         F         HCV         HCV         12         Infra renal like graft         RefX         Died of NOSF           36         M         HCV         10         Donor HA         RefX         Died of Septrations           50         M         AM of deficiency         Intermediate         20         Donor HA         RefX         Died of septrations           50         M         AM of deficiency         Intermediate         49         Donor HA         RefX         Died of septrations           50         M         AM of deficiency         Intermediate         49         Donor HA         RefX         Died of septrations           50         M         HCV         AMD         Intermediate         49         Donor HA         Nontract         Died of septrations           50         M         HCV         AMD         Intermediate         48         Donor HA         Nontract         Died of septrations           50         M         HCV         AMD         Intermediat	4	33.4	Σ	PSC		2	Donor HA	ReTx	Died of hepatic failure	34.0
5.3         F         BBC         10         Donor HA         RefX         Alwe           3.5         F         HCV         HCV         10         Donor HA         RefX         Ded of MOS*           3.6.7         M         HCV and HCC         16         Donor HA         RefX         Died of parcental the C           5.2.1         M         HCV and HCC         19         Donor HA         RefX         Died of parcentils           6.0         M         HCV and HCC         19         Donor HA         RefX         Died of parcentils           6.0         M         HCV and HCC         114         Donor HA         RefX         Died of recurrent HCC           6.0         M         HCV and HCC         114         Donor HA         Observation         Died of recurrent HCC           6.0         M         HCV and HCC         116         Donor HA         Observation         Died of recurrent HCC           8.5         M         HCV and HCC         116         Donor HA         RefX         Died of recurrent HCC           8.5         M         HCV and HCC         116         Donor HA         RefX         Died of recurrent HCC           8.5         M         HCV         118	5	44.3	ш	PBC		2	Donor HA	ReTx	Alive	168.2
35.7         F         HCV         12         Infra read liac gardt         Rei'x         Dued of MOSF           36.7         M         FLOH and HCV         19         Donor HA         Observation         Died of specularity           36.7         M         FLOH and HCV         19         Donor HA         Rei'x         Died of specularity           50.1         M         AH defricancy         Intermediate         49         Donor HA         Rei'x         Died of specularity           34.4         F         Auto-irrnune         49         Donor HA         Rei'x         Died of specularity           30.5         M         HCV         HCV         114         Infra renal ilea gart         Rei'x         Died of repart failure           50.5         M         HCV         HCV         145         Donor HA         Waitisted for Rei'x         Died of repart failure           50.5         M         HCV         HCV         17         Donor HA         Maintriend for Rei'x         Died of repart failure           50.5         M         HCV         HCV         17         Donor HA         Rei'x         Died of repart failure           50.5         M         HCV         Late         75         Infra renal iliac	9	65.3	ш	PBC		10	Donor HA	ReTx	Alive	167.0
38.5         F         HBV and HCC         16         Donor HA         Refr         Died of ageogliosis           5.1         M         HCV H and HCV         20         Right HA         Refr         Died of ageogliosis           5.2.1         M         HCV H and HCV         20         Right HA         Refr         Died of ageogliosis           5.2.1         M         HCV deficiency         Intermediate         46         Donor HA         Refr         Bid of partical lide of a geogliosis           6.0         M         HCV and HCC         116         Donor HA         Refr         Died of paparic failure           6.0         M         HCV and HCC         116         Donor HA         Donor HA         Died of paparic failure           6.0         M         HCV and HCC         116         Donor HA         Donor HA         Died of paparic failure           5.5         M         HCV and HCV         125         Donor HA         Donor HA         Died of paparic failure           5.5         M         HCV and HCV         148         Infra renal liac gaft         Refr         Died of reconent HCC           5.2         M         HCV and Anto-mounte         1350         Right HA         Refr         Died of reconent HCC <td>7</td> <td>35.7</td> <td>ш</td> <td>HCV</td> <td></td> <td>12</td> <td>Infra renal iliac graft</td> <td>ReTx</td> <td>Died of MOSF</td> <td>4.5</td>	7	35.7	ш	HCV		12	Infra renal iliac graft	ReTx	Died of MOSF	4.5
3.6.7         M         FICH and HCV         19         Donor HA         ReTX         Died of paperglicisis of asperglicisis           6.0         M         ALR deficiency         Intermediate         46         Donor HA         ReTX         Died of paperit failure           6.0         M         ALR deficiency         Intermediate         45         Donor HA         Died of paperit failure           6.0         M         HKV         114         Infra eval flice gaft         ReTX         Died of hepatic failure           6.0         M         HCV         116         Donor HA         Debervation         Died of hepatic failure           6.0         M         HCV and HCV         116         Donor HA         Malatised for ReTX         Died of hepatic failure           5.5.3         M         HEV         124         Donor HA         Malatised for ReTX         Died of hepatic failure           5.5.3         M         HEV         177         Donor HA         ReTX         Died of hepatic failure           5.5.3         M         HEV         177         Donor HA         ReTX         Died of hepatic failure           5.9.1         M         HEV         177         Donor HA         ReTX         Died of hepatic failure <td>∞</td> <td>38.5</td> <td>ш</td> <td>HBV and HCC</td> <td></td> <td>16</td> <td>Donor HA</td> <td>Observation</td> <td>Died of reccurent HCC</td> <td>20.4</td>	∞	38.5	ш	HBV and HCC		16	Donor HA	Observation	Died of reccurent HCC	20.4
52.1         M         HCV         20         Right HA         Reix         Died of panceatits           34.4         F         Autoeimmune         46         Donor HA         Reix         Died of paparic failure           34.4         F         Autoeimmune         49         Donor HA         Reix         Died of hepatic failure           60.6         M         HCV         HCV         116         Donor HA         Reix         Died of hepatic failure           60.6         M         HCV and HCV         116         Donor HA         Wailsted for Reix         Died of hepatic failure           66.6         M         HCV and HCV         116         Donor HA         Wailsted for Reix         Died of recurrent HCC           1.5.3         M         HCV         177         Donor HA         Reix         Died of hepatic failure           2.8.3         M         HCV         177         Donor HA         Reix         Died of hepatic failure           2.8.3         M         HEV         177         Donor HA         Reix         Died of bepatic failure           4.9.5         F         ETOH         366         Infra renal liag gaft         Reix         Died of hepatic failure           4.5.5         M </td <td>6</td> <td>36.7</td> <td>Σ</td> <td>ETOH and HCV</td> <td></td> <td>19</td> <td>Donor HA</td> <td>ReTx</td> <td>Died of aspergillosis</td> <td>0.5</td>	6	36.7	Σ	ETOH and HCV		19	Donor HA	ReTx	Died of aspergillosis	0.5
60         M         A1A deficiency         Intermediate         46         Donor HA         RPTX         Alive           33.4         F         Auto-immune         85         Origin of cellsc axis         Observation         Died of hepatic failure           39.1         M         HCV and HCC         114         Infra renal illac graft         RFIX*         Alive           66.6         M         HCV and HCC         116         Donor HA         Vaisitised for Rex         Died of hepatic failure           55.3         M         HCV and HCC         150         Donor HA         Maiditised for Rex         Died of begand from part callure           55.3         M         HBV         177         Donor HA         Reix*         Died of begand from part callure           55.3         M         HBV         177         Donor HA         Reix*         Died of begand frailure           55.2         M         HBV         177         Donor HA         Reix*         Died of resurent HCC           59.2         M         HCV         Auto-immune         136         Right HA         Reix         Died of resurent HCC           43.4         M         HCV         Auto-immune         136         Right HA         Reix         Die	10	52.1	Σ	HCV		20	Right HA	ReTx	Died of pancreatitis	5.0
344         F         Auto-immune         49         Donor HA         RFT**         Died of hepatic failure failure failure and lack graft         Rein Auto-immune         49         Died of hepatic failure failure failure and lack graft         Rein HEV         Auto-immune         49         Died of hepatic failure failure failure and lack graft         Rein HCV and HCC         114         Donor HA         Rein Auto-immune         Auto-immune         Died of heading failure fail	1	09	Σ	A1A deficiency	Intermediate	46	Donor HA	ReTx	Alive	158.1
60.6         M         HBV         85         Origin of celac axis         Observation         Died of hepatic failure           60.6         M         HCV         114         Infra areal liac gaft         RRT         Alive           60.6         M         HCV and HCC         116         Donor HA         Waitisted for ReFx         Died of inecturent HCC           49.5         F         BCS         152         Donor HA         Mathisted for ReFx         Died of inecturent HCC           28.3         M         HBW         Late         757         Infra areal liac gaft         ReTx         Died of inecturent HCC           28.9         M         HEV         Late         757         Infra areal liac gaft         ReTx         Died of inecturent HCC           43.7         M         HEV and ETOH         433         Infra areal liac gaft         ReTx         Died of incrurent HCV           43.4         M         CANDIS dieses         356         Infra areal liac gaft         ReTx         Died of incrurent HCV           43.7         M         HEV         200         Donor HA         ReTx         Died of incrurent HCV           43.4         M         ETOH         204         Infra renal liac gaft         ReTx         Died o	12	34.4	ш	Auto-immune		49	Donor HA	ReTx*	Died of hepatic failure	21.9
39.1         M         HCV         114         Infra renal lilac graft         ReTX         Alve           6.6         M         HCV and HCC         116         Donor HA         Observation         Died of beceing from Died of recurrent HCC           5.5         F         BCS         112         Donor HA         Observation         Died of beceing from Died of beceing from Died of beceing from Died of becking Died Died Died Died Died Died Died Died	13	9.09	Σ	HBV		85	Origin of celiac axis	Observation	Died of hepatic failure	15.3
60         M         HCV and HCC         116         Donor HA         Observation         Died of begeing HCC           49.5         F         BCS         162         Donor HA         Waitlisted for ReTx         Died of begeing from participal to predictive to prediction to participate to the participal to predictive to predictive to the total line and line and line are line and to the participal t	14	39.1	Σ	HCV		114	Infra renal iliac graft	ReTx	Alive	149.1
66 6         M         HCV         146         Donor HA         Waltisted for ReTX         Died of bleeding from pancratic for ReTX           49.5         F         BCS         162         Donor HA         RTX**         Died of bepate failune part fai	15	09	Σ	HCV and HCC		116	Donor HA	Observation	Died of reccurent HCC	1.6
9.5         F         BCS         162         Donor HA         ReTX*         Ded of repartic failure           5.3.7         M         HBV         177         Donor HA         Observation         Died of repartic failure           28.9         M         HBV         Late         757         Infra renal liac graft         ReTX         Died of recurrent HCZ           28.9         M         HCX         356         Infra renal liac graft         ReTX         Died of unknown cause           28.9         M         HCX         Auto-immune         338         Infra renal liac graft         ReTX         Died of unknown cause           45.6         F         F TDOH         506         Donor HA         ReTX         Alive           43.4         M         FTOH         2304         Infra renal liac graft         ReTX         Alive           59.3         M         FTOH         2304         Infra renal liac graft         ReTX         Alive           69.3         F         HCV         260         Donor HA         ReTX         Died of most frailure           69.3         F         HCV         260         Donor HA         ReTX         Died of frail mownown cause           69.3         F	16	9.99	Σ	HCV		146	Donor HA	Waitlisted for ReTx	Died of bleeding from	0.5
495         F         BCS         162         Donor HA         ReTx*         Died of hepatic failure           25.3         M         HBW         Late         757         Infra renal illac graft         RTX         Died of hepatic failure           28.9         M         Caroli's disease         1184         Donor HA         RTX         Died of hepatic failure           28.9         M         Caroli's disease         1184         Donor HA         RTX         Died of hepatic failure           59.2         M         HCV         And ETCH         433         Infra renal illac graft         RTX         Died of hepatic failure           19.5         M         ALLO         And ETCH         1462         Infra renal illac graft         RTX         Alive           43.4         M         ETOH         506         Donor HA         RTX         Died of hepatic failure           59.3         F         HCV         2304         Infra renal illac graft         RTX         Died of MOSF           69.3         F         HCV         250         Donor HA         Waitlisted for RTX         Died of MOSF           1.3         M         ETOH         520         Donor HA         Oiservation         Alive									pancreatic pseudocyst	
55.3         M         HBV         Late         757         Donor HA         Observation         Died of recurrent HCC           28.7         M         HBV         Late         757         Infra renal liac gaft         ReTX         Died of recurrent HCC           28.7         M         CAVC         366         Infra renal liac gaft         ReTX         Died of fundrown cause           43.7         M         HBV and ETOH         433         Infra renal liac gaft         ReTX         Died of fundrown cause           45.6         F         ETOH         506         Donor HA         ReTX         Alive           43.4         M         ETOH         506         Donor HA         ReTX         Alive           5.9         M         ETOH         506         Donor HA         ReTX         Alive           6.3         F         Cryptogenic         334         Infra renal liac gaft         ReTX         Died of MOSF           5.9         M         ETOH         230         Infra renal liac gaft         ReTX         Died of MOSF           6.3         F         Cryptogenic         339         Infra renal liac gaft         ReTX         Died of more of MOSF           5.1.3         M         A	17	49.5	ш	BCS		162	Donor HA	ReTx*	Died of hepatic failure	11.8
38.7         M         HBV         Late         757         Infra renal iliac graft         ReTX         Died of unknown cause           28.9         M         Caroli's disease         1184         Donor HA         ReTX         Died of unknown cause           43.7         M         HBV and ETOH         433         Infra renal iliac graft         ReTX         Died of hepatic failure           43.4         M         Auto-immune         1360         Infra renal iliac graft         ReTX         Died of hepatic failure           43.4         M         ETOH         506         Donor HA         ReTX         Died of hepatic failure           59.3         M         ETOH         506         Donor HA         ReTX         Died of Inknown cause           69.3         F         Cryptogenic         3204         Infra renal iliac graft         ReTX         Died of Inknown cause           69.3         F         Cryptogenic         320         Donor HA         Observation         Died of Inknown cause           51.3         M         All defricency         52         Donor HA         Observation         Died of Inknown cause           61.3         M         All defricency         52         Donor HA         Donor HA         Donor HA	18	55.3	Σ	HBV		177	Donor HA	Observation	Died of recurrent HCC	0.7
28.9         M         Caroli's disease         1184         Donor HA         ReTX         Died of MOSF           59.2         M         HCV         366         Infra renal iliac graft         ReTX         Died of hepatic failure           43.7         M         HUCV         433         Infra renal iliac graft         ReTX         Died of hepatic failure           43.4         M         ETOH         506         Donor HA         ReTX         Died of hepatic failure           69.3         F         ETOH         2304         Infra renal iliac graft         ReTX         Died of hepatic failure           69.3         F         ETOH         2304         Infra renal iliac graft         ReTX         Died of mknown cause           49         F         Cyptogenic         339         Infra renal iliac graft         Observation         Alive           49         F         Cyptogenic         339         Infra renal iliac graft         Observation         Died of mknown cause           51.3         M         AIA deficiency         540         Donor HA         Observation         Died of mknown cause           51.3         M         FC         Cyptogenic         540         Donor HA         Observation         Alive	19	38.7	Σ	HBV	Late	757	Infra renal iliac graft	ReTx	Died of unknown cause	75.5
59.2         M         HCV         366         Infra renal liac graft         ReTX         Died of recurrent HCV           43.7         M         HBV and ETOH         433         Infra renal liac graft         ReTX         Died of hepatic failure           45.6         F         ETOH         506         Donor HA         ReTX         Alive           59.3         F         ETOH         2304         Infra renal liac graft         ReTX         Died of MoSF           69.3         F         HCV         2304         Infra renal liac graft         ReTX         Died of MOSF           69.3         F         HCV         2304         Infra renal liac graft         ReTX         Died of mknown cause           49.9         F         HCV         ATA deficiency         540         Donor HA         Ashitisted for ReTX         Died of mknown cause           49.9         F         CVyptogenic         339         Infra renal liac graft         Observation         Alive           51.3         M         ATA deficiency         540         Donor HA         Observation         Died of Proportion           51.3         M         ETOH         1049         Donor HA         ReTX         Alive           5.1         M	20	28.9	Σ	Caroli's disease		1184	Donor HA	ReTx	Died of MOSF	4.7
43.7         M         HBV and ETOH         433         Infra renal iliac graft         ReTX         Died of hepatic failure           19.5         M         Auto-immune         1360         Right HA         ReTX         Alive           45.6         F         ETOH         506         Donor HA         ReTX         Died of MOSF           43.4         M         ETOH         2304         Infra renal iliac graft         ReTX         Died of MOSF           69.3         F         HCV         260         Donor HA         Waltlisted for ReTX         Died of MOSF           49         F         HCV         250         Donor HA         Waltlisted for ReTX         Died of unknown cause           49         F         HCV         250         Donor HA         Waltlisted for ReTX         Died of MOSF           49         F         HCV         540         Donor HA         Observation         Died of hepatic failure           51.3         M         FC         Billiary atresia         1         Donor HA         Observation         Alive           6         F         Billiary atresia         1         Donor HA         ReTX         Alive           7         M         Billiary atresia <t< td=""><td>21</td><td>59.2</td><td>Σ</td><td>HCV</td><td></td><td>366</td><td>Infra renal iliac graft</td><td>ReTx</td><td>Died of recurrent HCV</td><td>0.3</td></t<>	21	59.2	Σ	HCV		366	Infra renal iliac graft	ReTx	Died of recurrent HCV	0.3
19.5         M         Auto-immune         1360         Right HA         ReTX         Alive           45.6         F         ETOH         506         Donor HA         ReTX         Died of MOSF           43.4         M         ETOH         2304         Infra renal lilac graft         ReTX         Died of MOSF           69.3         F         Cryptogenic         230         Infra renal lilac graft         ReTX*         Died of MOSF           49         F         Cryptogenic         339         Infra renal lilac graft         Observation         Alive           49         F         Cryptogenic         339         Infra renal lilac graft         Observation         Alive           51.3         M         A1A deficiency         540         Donor HA         Observation         Died of PTLD and hepatic failure           46.9         M         PSC         1438         Donor HA         Observation         Alive           46.9         M         Biliary atresia         1         Donor HA         ReTX         Alive           6.6         F         Biliary atresia         1         Donor HA         ReTX         Alive           7         R         Histiocytosis         2         Donor	22	43.7	Σ	HBV and ETOH		433	Infra renal iliac graft	ReTx	Died of hepatic failure	29.2
45.6         F         ETDH         1462         Infra renal lilac graft         ReTx         Died of MOSF           43.4         M         ETOH         2304         Infra renal lilac graft         ReTx*         Died of MOSF           69.3         F         HCV         260         Donor HA         Waltisted for ReTx*         Died of MOSF           49         F         Cryptogenic         339         Infra renal lilac graft         Observation         Died of MOSF           51.3         M         A1A deficiency         540         Donor HA         Observation         Died of PTLD and Prepatic failure           51.3         M         ETOH         1049         Donor HA         Observation         Died of PTLD and Prepatic failure           46.9         M         PSC         1438         Donor HA         Observation         Alive           46.9         M         Billiary atresia         1         Donor HA         ReTx         Alive           0.6         F         Billiary atresia         10         Donor HA         ReTx         Alive           0.6         F         Billiary atresia         10         Donor HA         ReTx         Alive           1.7         F         Billiary atresia	23	19.5	Σ	Auto-immune		1360	Right HA	ReTx	Alive	120.4
45.6         F         ETOH         1462         Infra renal liac graft         ReTx         Alive           43.4         M         ETOH         506         Donor HA         ReTx         Died of MOSF           59         M         ETOH         2304         Infra renal liac graft         ReTx*         Died of MOSF           69.3         F         Cryptogenic         339         Infra renal liac graft         Observation         Alive           49         F         Cryptogenic         339         Infra renal liac graft         Observation         Alive           51.3         M         A1A deficiency         540         Donor HA         Observation         Died of MOSF           46.9         M         FTOH         1049         Donor HA         Observation         Died of hepatic failure           46.9         M         PSC         1438         Donor HA         ReTx         Alive           5.1         M         Biliary atresia         1         Donor HA         ReTx         Alive           6.6         F         Biliary atresia         1         Donor HA         ReTx         Alive           9.6         F         Biliary atresia         1         Donor HA         Re				and HCV						
43.4         M         ETOH         506         Donor HA         ReTx*         Died of MOSF           59         M         ETOH         2304         Infra renal iliac graft         ReTx*         Died of unknown cause           69.3         F         HCV         260         Donor HA         Waitlisted for ReTx         Died of unknown cause           49         F         Cryptogenic         339         Infra renal iliac graft         Observation         Alive           51.3         M         A1A deficiency         540         Donor HA         Observation         Died of PTLD and hepatic failure           46.9         M         FSC         1438         Donor HA         Observation         Died of hepatic failure           ildren         F         Biliary atresia         1         Donor HA         ReTx         Alive           0.6         F         Biliary atresia         1         Donor HA         ReTx         Alive           0.6         F         Biliary atresia         1         Donor HA         ReTx         Alive           3.1         M         Histiocytosis         2         Donor HA         ReTx         Alive           3.1         M         Histiocytosis         2	24	45.6	ш	ЕТОН		1462	Infra renal iliac graft	ReTx	Alive	109.8
59         M         ETOH         2304         Infra renal ilac graft         ReTx*         Died of unknown cause           69.3         F         HCV         260         Donor HA         Waitlisted for ReTx         Died of MOSF           49         F         Cryptogenic         339         Infra renal ilac graft         Observation         Alive           38.4         M         A1A deficiency         540         Donor HA         Observation         Died of PTLD and Pepatic failure           46.9         M         FCOH         1049         Donor HA         Observation         Died of Prpatic failure           1idren         A5.9         M         Biliary atresia         1         Donor HA         ReTx         Alive           2.7         M         Biliary atresia         1         Donor HA         ReTx         Alive           0.6         F         Biliary atresia         1         Donor HA         ReTx         Alive           3.1         M         Histiocytosis         2         Donor HA         ReTx         Alive           1.7         F         Biliary atresia         5         Donor HA         ReTx         Alive	25	43.4	Σ	ETOH		206	Donor HA	ReTx	Died of MOSF	27.5
69.3         F         HCV         260         Donor HA         Waitlisted for ReTX         Died of MOSF           49         F         Cryptogenic         339         Infra renal iliac graft         Observation         Alive           38.4         M         A1A deficiency         540         Donor HA         Observation         Died of PTLD and hepatic failure           51.3         M         FTOH         1049         Donor HA         Observation         Died of hepatic failure           46.9         M         PSC         1438         Donor HA         Observation         Alive           idren         Biliary atresia         1         Donor HA         ReTX         Alive           0.6         F         Biliary atresia         1         Donor HA         ReTX         Alive           3.1         M         Histiccytosis         2         Donor HA         ReTX         Alive           1.7         F         Biliary atresia         5         Donor HA         ReTX         Died of hepatic failure	56	59	Σ	ЕТОН		2304	Infra renal iliac graft	ReTx*	Died of unknown cause	4.7
49         F         Cryptogenic         339         Infra renal iliac graft         Observation         Alive           38.4         M         A1A deficiency         540         Donor HA         Observation         Died of PTLD and hepatic failure           51.3         M         ETOH         1049         Donor HA         Observation         Died of hepatic failure           46.9         M         PSC         1438         Donor HA         Observation         Alive           idren         L         Biliary atresia         1         Donor HA         ReTx         Alive           0.6         F         Biliary atresia         10         Donor HA         ReTx         Alive           3.1         M         Histicoytosis         2         Donor HA         ReTx         Alive           1.7         F         Biliary atresia         5         Donor HA         ReTx         Died of hepatic failure	27	69.3	ш	HCV		260	Donor HA	Waitlisted for ReTx	Died of MOSF	0.5
38.4         M         A1A deficiency         540         Donor HA         Observation         Died of PTLD and hepatic failure hepatic failure hepatic failure           51.3         M         ETOH         1049         Donor HA         Observation         Died of hepatic failure hepatic failure           46.9         M         PSC         1438         Donor HA         Observation         Alive           2.7         M         Biliary atresia         1         Donor HA         ReTx         Alive           0.6         F         Biliary atresia         10         Donor HA         ReTx         Alive           3.1         M         Histicoytosis         2         Donor HA         ReTx         Alive           1.7         F         Biliary atresia         5         Donor HA         ReTx         Died of hepatic failure	28	49	ш	Cryptogenic		339	Infra renal iliac graft	Observation	Alive	128.6
51.3         M         ETOH         1049         Donor HA         Observation         Died of hepatic failure           46.9         M         PSC         1438         Donor HA         Observation         Died of hepatic failure           2.7         M         Biliary atresia         13         Donor HA         ReTx         Alive           0.6         F         Biliary atresia         10         Donor HA         ReTx         Alive           3.1         M         Histicoytosis         2         Donor HA         ReTx         Alive           1.7         F         Biliary atresia         5         Donor HA         ReTx         Died of hepatic failure	59	38.4	Σ	A1A deficiency		540	Donor HA	Observation	Died of PTLD and	84.2
51.3         M         ETOH         1049         Donor HA         Observation         Died of hepatic failure           46.9         M         PSC         1438         Donor HA         Alive           2.7         M         Biliary atresia         1         Donor HA         ReTx         Alive           0.6         F         Biliary atresia         10         Donor HA         ReTx         Alive           3.1         M         Histiocytosis         2         Donor HA         ReTx         Alive           1.7         F         Biliary atresia         5         Donor HA         ReTx         Died of hepatic failure									hepatic failure	
46.9         M         PSC         1438         Donor HA         Observation         Alive           ildren         2.7         M         Biliary atresia         13         Donor HA         ReTx         Alive           0.6         F         Biliary atresia         10         Donor HA         ReTx         Alive           3.1         M         Histiocytosis         2         Donor HA         ReTx         Alive           1.7         F         Biliary atresia         5         Donor HA         ReTx         Died of hepatic failure	30	51.3	Σ	ETOH		1049	Donor HA	Observation	Died of hepatic failure	5.0
idren         2.7         M         Biliary atresia         13         Donor HA         ReTx         Alive           0.6         F         Biliary atresia         10         Donor HA         ReTx         Alive           3.1         M         Histiocytosis         2         Donor HA         ReTx         Alive           1.7         F         Biliary atresia         5         Donor HA         ReTx         Died of hepatic failure	31	46.9	Σ	PSC		1438	Donor HA	Observation	Alive	107.2
2.7MBiliary atresia13Donor HAReTxAlive0.6FBiliary atresia10Donor HAReTxAlive3.1MHistiocytosis2Donor HAReTxAlive1.7FBiliary atresia5Donor HAReTxDied of hepatic failure	Children									
0.6FBiliary atresia1Donor HAReTxAlive0.6FBiliary atresia10Donor HAReTxAlive3.1MHistiocytosis2Donor HAReTxAlive1.7FBiliary atresia5Donor HAReTxDied of hepatic failure	32	2.7	Σ	Biliary atresia		13	Donor HA	ReTx	Alive	68.1
0.6     F     Biliary atresia     10     Donor HA     ReTx     Alive       3.1     M     Histiocytosis     2     Donor HA     ReTx     Alive       1.7     F     Biliary atresia     5     Donor HA     ReTx     Died of hepatic failure	33	9.0	ட	Biliary atresia		<b>—</b>	Donor HA	ReTx	Alive	172.6
M Histiocytosis 2 Donor HA ReTx Alive F Biliary atresia 5 Donor HA ReTx Died of hepatic failure	34	9.0	ш	Biliary atresia		10	Donor HA	ReTx	Alive	171.9
F Biliary atresia 5 Donor HA ReTx Died of hepatic failure	35	3.1	Σ	Histiocytosis		7	Donor HA	ReTx	Alive	167.8
	36	1.7	ட	Biliary atresia		2	Donor HA	ReTx	Died of hepatic failure	9.0

167.2	e 0.0	1.1	164.4	165.5	55.2	
Alive	Died of hepatic failure	Died of hepatic failure	Alive	Alive	Alive	
Observation	Streptokinase embolectomy	Observation	Observation	Re-anastomosis	Observation†	
Donor HA	Donor HA	Donor HA	Donor HA	Donor HA	Right HA	
∞	-	10	7	-	_	
Biliary atresia	Biliary atresia	Biliary atresia	Biliary atresia	Biliary atresia	Giant cell hepatitis	
ட	Σ	Σ	Σ	Σ	Σ	
0.4	_	1.1	1.2	0.5	1.5	:
37	38	39	40	41	42	

Pt., patient; LTx, liver transplant; ReTx, re-transplantation; HA, hepatic artery; HBV, hepatitis B viral disease; HCV, hepatitis C viral disease; ETOH, alcohol related disease; A1A, alpha 1 antitrypsin; PSC, primary sclerosing cholangitis; PBC, primary biliary cirrhosis; BCS, budd chiari syndrome; PTLD, post-transplant lymphoproliferative disease; MOSF, multi-organ system failure. \*Underwent second ReTx re-transplantation, are alive at 120, 110, 129 and 107 months respectively, after diagnosis of HAT. One patient required a third transplant after HAT of second graft (case 26).

# Management of nonthrombotic complications (stenosis, kink, pseudo-aneurysm)

# Anastomotic stenosis

There were 11 anastomotic stenoses, one in a child (case 53) and 10 in adults (cases 43–52). The child underwent balloon angioplasty and he is alive for 13 years 9 months postangioplasty. Two adults were re-transplanted (cases 43 and 52), one of them had an infra-renal aorto-iliac graft. Two patients (cases 49 and 50) underwent balloon angioplasty and the other six patients were under observation. Four adult patients survived and six expired.

#### Nonanastomotic stenoses

Five adult patients (cases 54-58) had stenosis of the donor hepatic artery proximal to anastomosis. Three of these patients were treated with re-transplantation (n=2) and angioplasty (n=1). The remaining two patients were not suitable for any intervention and were under observation. One of them is currently alive. The remaining four patients died at 2.1, 2.3, 21.3 and 81.2 months after diagnosis of stenosis.

Four adult patients had a redundant length of artery resulting in a kink (cases 59–62). In three patients, the kink was in the hepatic artery and one patient had an infra-renal aorto-iliac graft kink (case 62). One patient was re-transplanted (case 59), two underwent balloon angioplasty (cases 60 and 62) and one patient was under observation. Two patients died at 22.3 and 79.4 months and the other two are currently alive.

Six adult patients (cases 63–68) had either an isolated stenosis in the right hepatic artery (n=2, cases 66 and 68), in the recipient celiac artery at its origin (case 64), an anastomotic stenosis with celiac artery stenosis at its origin (case 63), a left hepatic artery stenosis (case 65) or stenosis of both the left and the right hepatic artery (case 67). Among these six patients two were re-transplanted (cases 64 and 67), one underwent balloon angioplasty (case 62), two were under observation (cases 65 and 66) and the remaining one died while awaiting re-transplantation (case 63).

Four adults (cases 69–72) were found to have hepatic artery pseudo-aneurysm at 1, 77, 139 and 482 days after LTx. One of them (case 72) underwent re-transplantation and is alive for 10 years and 5 months after LTx. The remaining three patients (cases 69–71) died at 2.5, 31.9 and 83.6 months after diagnosis of pseudo-aneurysm

Table 3. Demographics and outcome of nonthrombotic complications.

No.	Age at LTx (years)	Gender	Primary diagnosis	Complication and anatomical site	Time to diagnosis (days from LTx)	Donor age (years)	Management	Outcome	Patient survival (months)
43	32.8	Σ	ЕТОН	Anastomotic stenosis	21	39	ReTx	Alive	166.2
4	64.3	Σ	HCV	Anastomotic stenosis	150	51	Observation	Alive	42.6
45	73.6	ட	Cryptogenic	Anastomotic stenosis	31	27	Observation	Died of MOSF	1.6
46	42	ட	HBV	Anastomotic stenosis	41	19	Observation	Died of MOSF	2.6
47	43	Σ	ETOH and HCV	Anastomotic stenosis	53	17	Observation	Died of pneumonia	69.3
48	51.9	Σ	HBV	Anastomotic stenosis	87	28	Observation	Died of PTLD	153.0
49	51	Σ	ЕТОН	Anastomotic stenosis	10	14	Balloon angioplasty	Died of recurrent HCC	69.4
20	56.9	Σ	HCV	Anastomotic stenosis	148	39	Balloon angioplasty	Alive	24.8
21	42.9	Σ	HCV and ETOH	Anastomotic stenosis	16	42	Observation	Alive	79.0
52	31.8	ட	ЕТОН	Anastomotic stenosis	101	49	ReTx	Died of aspergillosis	5.6
				of iliac graft					
53	0.5	Σ	Biliary atresia	Anastomotic stenosis	268		Balloon angioplasty	Alive	141.6
54	59.7	ட	PBC	Proximal HA stenosis	54	24	ReTx	Died of MOSF	2.1
22	46.9	Σ	ЕТОН	Proximal HA stenosis	138	42	ReTx	Died of broncho pneumonia	21.2
99	62.9	ட	PBC	Proximal HA stenosis	55	58	Observation	Died of MOSF	2.3
22	7.07	Σ	ЕТОН	Proximal HA stenosis	118	26	Balloon angioplasty	Died of pneumonia	6.08
28	65.4	ட	PBC	Proximal HA stenosis	413	53	Observation	Alive	141.7
29	31.8	Σ	HCV	Kink in HA	87	33	ReTx	Died of MOSF	22.3
09	75	ட	ЕТОН	Kink in HA	131	26	Balloon angioplasty	Died of pneumonia	146.5
19	43.9	ட	Tylenol toxicity	Kink in HA	58	27	Observation	Alive	143.0
62	38.1	Σ	A1A deficiency	Kink in iliac graft	2501	16	Balloon angioplasty	Alive	179.3
63	57.7	ட	HBV	Anastomotic stenosis	17	51	Died on waiting list for ReTx	Died of hepatic failure	6.0
				and celiac axis stenosis					
64	53.1	ட	ЕТОН	Celiac axis stenosis	Υ.	45	ReTx	Alive	154.8
9	18.1	Σ	Cryptogenic	Left HA stenosis	2	53	Observation	Alive	141.1
99	64.5	Σ	HCV	Right HA stenosis	165	43	Observation	Died of MOSF	5.8
29	19.9	ட	Cystic fibrosis	Right and left HA stenosis	81	56	ReTx	Died of MOSF	4.7
89	40.8	ட	ETOH and HCV	Right HA stenosis	53	42	Balloon angioplasty	Died of recurrent HCV	10.5
69	8.59	ட	HCV	Pseudo-aneurysm	77	29	Resection of aneurysm	Died of recurrent HCV	31.9
							and reconstruction		
70	48.8	Σ	PNC non-A non-B	Pseudo-aneurysm	_	27	Observation	Died of MOSF	2.5
71	40.9	ட	HCV	Pseudo-aneurysm	139	25	Percutaneous embolization	Died of recurrent HCV	83.6
72	58.4	ш	Cryptogenic	Pseudo-aneurysm	482	09	Failed recostruction,	Alive	141.0
							ligation, ReTx		

LTx, liver transplant; ReTx, re-transplantation; HA, hepatic artery; HBV, hepatitis B viral disease; HCV, hepatitis C viral disease; ETOH, alcohol related disease; A1A, alpha 1 antitrypsin; PBC, primary biliary cirrhosis; PTLD, post-transplant lymphoproliferative disease; MOSF, multiorgan system failure.

because of multi-organ failure or recurrent HCV and hepatic failure (Table 3).

# Survival outcome

# Patient survival

Overall 13-year patient survival after HAT was 43.2%. It was 72.7% for children and 32.9% for adults. This

difference was not statistically significant (P=0.088) (Fig. 1a and b). Among adults with thrombosis, the 13-year patient survival was 40%, 29.2% and 30.8% when they developed early, intermediate and late thrombosis, respectively, after LTx (P=0.995) (Fig. 1b). In adult patients who developed nonthrombotic complications the 13 year survival was 45.7% (Fig. 2b). Causes of death with thrombotic and nonthrombotic complications




Figure 1 Patient and graft survival. (a) Overall patient and graft survival. (b) Patient survival in children and adults with early, intermediate and late hepatic artery thrombosis.

Hepatic artery thrombosis Jain et al.

with and without re-transplantation are summarized in Table 4.

# Graft Survival

Overall 13-year graft survival after diagnosis of thrombosis was 15.1% (Fig. 1a). It was 36.4% in children and 7.0% in adults. This difference was not statistically significant (P=0.155) (Fig. 2a). Among adults with thrombosis, the 13-year graft survival values were 0%, 0% and 15% when they developed early, intermediate and late

thrombosis, respectively, after LTx (P=0.029) (Fig. 2a). The 13-year graft survival for nonthrombotic complications was 30.4% in adults (Fig. 2b) and 100% in children.

# Discussion

Hepatic artery complications after LTx are well known and well documented [11,12]. It is one of the most common complications after LTx and has significant impact on graft and patient survival. The present report describes




Figure 2 Patient and graft survival. (a) Graft survival in children and adults with early, intermediate and late hepatic artery thrombosis. (b) Patient and graft survival in adult patients with nonthrombotic complications.

Table 4. Causes of death.

	Without Re-Tx	With Re-Tx	Total
Hepatic artery throm	bosis		
Sepsis	0	1	1
Graft failure	4	5	9
MOSF	1	3	4
Recurrent HCC	3	0	3
Aspergilliosis	0	1	1
Pancreatitits	0	1	1
Bleeding	1	0	1
Recurrent HCV	0	1	1
PTLD	1	0	1
Unknown cause	0	2	2
Total	10	14	24
Nonthrombotic			
MOSF	5	3	8
Graft failure	1	0	1
Pneumonia	3	1	4
PTLD	1	0	1
Recurrent HCC	1	0	1
Recurrent HCV	3	0	3
Aspergilliosis	0	1	1
Subtotal	14	5	19

Re-Tx, re-transplant; MOSF, multiorgan failure; HCV, hepatitis C viral infection; PTLD, post-transplant lympho-proliferative disease; HCC, hepatocellular carcinoma.

the impact of various types of arterial complications after LTx and its long-term impact on patient and graft survival. A striking difference in adult and pediatric populations in terms of rate of complications, types of complications, timing of complications and survival outcomes after LTx is apparent in the present report.

The overall rate of HAT in children was almost twice that of the rate in the adult population. However, this difference was not statistically significant. Moreover, while all HAT in children occurred within the first 2 weeks, in adults, only one third of HAT was noticed in the first month post-LTx. At 14 years after HAT, 72% of children were alive compared with 32.9% of the adult population, which also did not reach statistical significance. Settmacher et al. [13] described a rate of 2.7% for HAT and 3.22% for stenosis in 1000 LTx patients, which is comparable with our findings. However, higher rates of HAT have been reported by Mas et al. [14] (7%) and Parera et al. [15] (8.8%). Mas et al. [14] also found prothrombin G20210A polymorphism in two of 14 hepatic allograft DNA. Fifty percent of children and 67.74% of adults underwent re-transplantation. For the adult population, this was 90% with early thrombosis, 50% with intermediate and 61.6% with late thrombosis.

Patient survival at 1, 5 and 10 years after re-transplantation in adults was 57.1%, 42.9%, 37.5% and that in children was 80%, 80%, and 80%. Survival in children

after HAT is better than in adults as children are more resilient and bounce back quickly. Moreover, some adults have associated age-related co-morbid conditions, which adds to the overall mortality, not to mention the recurrence of viral, auto-immune, recurrent or *de novo* malignancy [1,4]. Postma *et al.* [16] recently reported better survival after re-transplantation because of HAT compared with re-transplantation due to other causes.

In the adult population, graft survival was 0% by the end of 2 years for early and intermediate thrombosis, while this was 30.8% at 2 years and 11.4% by 11 years for late thrombosis. This was mainly due to the development of collateral circulation and re-canalization as seen by Tian *et al.* [17]. Valente *et al.* [18] have described a relatively benign course of late HAT.

Nonthrombotic complication among children was surprisingly found in only one child (0.6%) who was treated successfully by balloon angioplasty. In adults, a variety of nonthrombotic complications were encountered like anastomotic stenosis, postanastomotic proximal hepatic artery stenosis, redundant arterial length with kink, stenosis at the origin of celiac axis, pseudo-aneurysm at the anastomotic site and various combinations of these. They were managed by re-transplantation in 26.67% patients, angioplasty in 24.2%, and the remaining patients were under observation. While the only child who suffered this complication survived, the patient and graft survival for adult population was disappointingly low at 45.7% and 34.4%, respectively, at 13 years.

In the adult population, infra-renal aorto-iliac graft was either thrombosed or stenosed in eight patients accounting for 13.2% of all arterial complications, most of them occurring as a late complication. Unfortunately the exact number of patients who received infra-renal aorto-iliac graft is not known in this retrospective study. Stange et al. [19] have reported a HAT rate of 2.17% in the adult population of 1192 LTx that increased to 5.76 fold when interposition graft to supraceliac aorta was used. Muralidharan et al. [20] have reported a 1-5 year patency rate of 88.5-80.8% when arterial conduits were used for hepatic artery revascularization in adult LTx. Muiesan et al. [21] have suggested interpositional arterial graft from the cadaveric superior mesenteric artery with higher success rate. This type of reconstruction was not performed in this population. Arterial anatomical variations have also been described as a risk factor [5,6]. In the present retrospective analysis, this information was also not available.

The incidence is higher in smaller children where the lumen is smaller and with even a small degree of hypotension due to any cause can lead to HAT. Hepatic artery with small diameter and lower blood flow are very well described risk factors for thrombosis. Mazzaferro *et al.* [8] described a hepatic artery diameter of <3 mm as a

Hepatic artery thrombosis Jain et al.

risk factor. Lin et al. [7] have observed that arterial flow lower than 200 ml/min increased the rate of HAT by a factor 5. This has been the main reason why the rate of HAT in children was almost twice as much compared with adults. Interestingly nine of the 11 children who developed HAT were <2 years and the other two were 2.7 and 3.1 years of age. HAT was not observed in children who were >3.1 years of age. Rela et al. [22] described a higher rate of HAT in children <5 years of age and prolonged cold ischemic time as a risk factor, which also support our findings. However, using higher magnification either with the optical loupe or microscope, the rate has now decreased in pediatric population. Recently, Guarrera et al. [23] published excellent reports in 28 cases of segmental pediatric LTx using operative microscope with 12-16·magnification (n = 14) and loupe optics with 6× magnification without any incidence of HAT.

Various studies [5–9] have described hypercoagulable state as an independent risk factor. However, this was not worked up in these patients. In the present series, anticoagulation therapy in the first week was used routinely in children as suggested by Heffron et al. [24] and Abou Ella et al. [25]. In the past, we have described the use of hyperbaric oxygen therapy for HAT in children [26]. However, in the present series none of the children received this treatment. All HAT in children occurred in the early postoperative period while in the adult population it appears to occur early as well as late after LTx. Late HAT adults may be related to donor or recipient age. Often there is a history of hypertension or diabetes either in the donor and/or recipient, which is known to affect the intima of the artery and wall thickness. This may be the reason why late hepatic arterial complications and postanastomotic strictures are seen in children. This aspect in transplant population has not been examined. Moreover, the hypercoagulable state is not routinely worked up in transplant population. We feel that the hypercoagulable state in the adult population should be investigated more routinely to prevent late HAT.

Moreover, redundancy of hepatic artery resulting in kinking has been observed in this report. We suggest that when there is a redundancy, instead of entire length of donor hepatic artery with aortic cuff, a shorter length with patch at the level of splenic artery branch may be a better option. Also a small piece of omentum in continuity to prevent kink behind the anastomosis may be useful.

Postanastomotic stenosis is most likely from the clamp used on donor hepatic artery which may be causing some intimal damage resulting in stenosis at a later date. It may be possible that the rate of such stenosis may be even higher than reported here as routine surveillance ultrasound examination was not performed in this population. It is now routine to have duplex color ultrasound at 1 year in all adult patients at this institution. Outcome of such practice is awaited with great anticipation.

# Conclusion

In the present series with long-term follow-up, 4.2% of patients with thrombotic and 3.2% with nonthrombotic complications were under observation. The incidence of HAT was higher in children than in adults and occurred significantly earlier. Survival outcome was better in children than in adults. Nonthrombotic complications were significantly higher in adults than in children and had a significant impact in terms of graft and patient survival. It may be preventable in some cases by reducing the redundancy in the donor hepatic artery with careful clamping and handling. Routine workup of hypercoagulable state in adults, surveillance duplex ultrasound, and use of higher magnification for arterial reconstruction in smaller children and anticoagulation therapy may reduce the overall incidence of HAT.

# Acknowledgements

We acknowledge the help of Dr Manoj Purohit in finalizing the manuscript.

This study was supported by internal funding only.

# **Conflicts of interest**

There are no conflicts of interest associated with this study.

#### References

- 1. Jain A, Reyes J, Kashyap R, *et al.* Long-term survival after liver transplantation in 4000 consecutive patients at a single center. *Ann Surg* 2000; **232**: 490.
- 2. Jain A, Demetris AJ, Kashyap R, *et al.* Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1048 liver transplantations with a mean follow-up of 6 years. *Liver Transpl* 2001; 7: 623.
- Jain A, Mazariegos G, Pokharna R, et al. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis. *Transplantation* 2003; 75: 1020.
- Jain A, Reyes J, Kashyap R, et al. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann Surg 1999; 230: 441.

5. Hardy KJ, Jones RM. Hepatic artery anatomy in relation to reconstruction in liver transplantation: some unusual variations. *Aust N Z J Surg* 1994; **64**: 437.

- Ishigami K, Zhang Y, Rayhill S, Katz D, Stolpen A. Does variant hepatic artery anatomy in a liver transplant recipient increase the risk of hepatic artery complications after transplantation? *AJR Am J Roentgenol* 2004; **183**: 1577.
- 7. Lin M, Crawford M, Fisher J, Hitos K, Verran D. Hepatic artery thrombosis and intraoperative hepatic artery flow rates in adult orthotopic liver transplantation. *ANZ J Surg* 2002; 72: 798.
- 8. Mazzaferro V, Esquivel CO, Makowka L, *et al.* Hepatic artery thrombosis after pediatric liver transplantation a medical or surgical event? *Transplantation* 1989; **47**: 971.
- 9. Tisone G, Gunson BK, Buckels JA, McMaster P. Raised hematocrit a contributing factor to hepatic artery thrombosis following liver transplantation. *Transplantation* 1988; **46**: 162.
- 10. Jain AB, Fung JJ, Todo S, *et al.* One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events. *Transplant Proc* 1995; **27**: 1099.
- 11. Todo S, Makowka L, Tzakis AG, *et al.* Hepatic artery in liver transplantation. *Transplant Proc* 1987; **19** (1 Pt 3): 2406.
- 12. Tzakis AG, Gordon RD, Shaw BW Jr, Iwatsuki S, Starzl TE. Clinical presentation of hepatic artery thrombosis after liver transplantation in the cyclosporine era. *Transplantation* 1985; **40**: 667.
- 13. Settmacher U, Stange B, Haase R, et al. Arterial complications after liver transplantation. Transpl Int 2000; 13: 372.
- Mas VR, Fisher RA, Maluf DG, Wilkinson DS, Garrett CT, Ferreira-Gonzalez A. Hepatic artery thrombosis after liver transplantation and genetic factors: prothrombin G20210A polymorphism. *Transplantation* 2003; 76: 247.
- 15. Parera A, Salcedo M, Vaquero J, *et al.* Arterial complications after liver transplantation: early and late forms. *Gastroenterol Hepatol* 1999; **22**: 381.

- 16. Postma R, Haagsma EB, Peeters PM, van den Berg AP, Slooff MJ. Retransplantation of the liver in adults: outcome and predictive factors for survival. *Transpl Int* 2004; 17: 234.
- 17. Tian MG, Tso WK, Lo CM, Liu CL, Fan ST. Treatment of hepatic artery thrombosis after orthotopic liver transplantation. *Asian J Surg* 2004; 27: 213.
- 18. Valente JF, Alonso MH, Weber FL, Hanto DW. Late hepatic artery thrombosis in liver allograft recipients is associated with intrahepatic biliary necrosis. *Transplantation* 1996; **61**: 61.
- 19. Stange BJ, Glanemann M, Nuessler NC, Settmacher U, Steinmuller T, Neuhaus P. Hepatic artery thrombosis after adult liver transplantation. *Liver Transpl* 2003; **9**: 612.
- 20. Muralidharan V, Imber C, Leelaudomlipi S, *et al.* Arterial conduits for hepatic artery revascularisation in adult liver transplantation. *Transpl Int* 2004; 17: 163.
- 21. Muiesan P, Rela M, Heaton ND. Use of cadaveric superior mesenteric artery as interpositional vascular graft in orthotopic liver transplantation. *Br J Surg* 2001; **88**: 70.
- 22. Rela M, Muiesan P, Bhatnagar V, *et al.* Hepatic artery thrombosis after liver transplantation in children under 5 years of age. *Transplantation* 1996; **61**: 1355.
- Guarrera JV, Sinha P, Lobritto SJ, Brown RS Jr, Kinkhabwala M, Emond JC. Microvascular hepatic artery anastomosis in pediatric segmental liver transplantation: microscope vs loupe. *Transpl Int* 2004; 17: 585.
- Heffron TG, Pillen T, Welch D, Smallwood GA, Redd D, Romero R. Hepatic artery thrombosis in pediatric liver transplantation. *Transplant Proc* 2003; 35: 1447.
- 25. Abou Ella KA, Al Sebayel MI, Ramirez CB, Rabea HM. Hepatic artery thrombosis after orthotopic liver transplantation. *Saudi Med J* 2001; **22**: 211.
- Mazariegos GV, O'Toole K, Mieles LA, et al. Hyperbaric oxygen therapy for hepatic artery thrombosis after liver transplantation in children. *Liver Transpl Surg* 1999; 5: 429.